Stenabolic (SR9009): A Literature Course in Six Modules

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. It summarises what published studies of Stenabolic (SR9009) and the REV-ERB pathway reported, and it does not describe how any compound should be used.

Module 1 — What Stenabolic Is, and How It Has Been Studied

Definition and class

Stenabolic is the nickname attached to the research compound SR9009. It is not a peptide, not an anabolic steroid, and not a selective androgen receptor modulator. It is a synthetic, non-peptide small molecule described as an agonist of the REV-ERB nuclear receptors, REV-ERBα (gene NR1D1) and REV-ERBβ (gene NR1D2), which are heme-binding transcriptional repressors embedded in the molecular circadian clock. It appears in the pharmacology literature as one of a pair of related tool compounds, SR9009 and SR9011, introduced in a 2012 Nature paper describing the identification of potent synthetic REV-ERB agonists and their effects on circadian behaviour and metabolism in mice (PMID 22460951).

Origin

The compound originated as a chemical probe: a molecule made to interrogate what happens when a clock receptor is pharmacologically switched, rather than as a drug candidate developed for a defined indication. The 2012 report framed SR9009 and SR9011 as agonists able to modulate circadian amplitude and period, and reported that in vivo administration altered the circadian expression of core clock and metabolic genes in liver, skeletal muscle and adipose tissue of mice (PMID 22460951). Later work used the same molecules as pharmacological counterparts to genetic manipulation of REV-ERB, for example in a 2018 Nature study of cancer and senescent cells (PMID 29320480).

Forms encountered

• Laboratory-grade powder or solvent stock, labelled research use only, used in cell culture and animal work.
• No approved tablet, capsule, injection or other pharmaceutical dosage form exists in any major jurisdiction (see Module 6).
• The name "Stenabolic" is a marketing-style label, not a pharmacopoeial or International Nonproprietary Name; the peer-reviewed literature uses SR9009.

How the evidence base is built

Three kinds of paper make up the readable literature: (1) studies that administered SR9009 or SR9011 to rodents or cells; (2) genetic studies that deleted or overexpressed Nr1d1/Bmal1 to define what the pathway does; and (3) studies of unrelated clock-targeting molecules that establish how plastic the system is, such as a 2024 report that nobiletin promoted lipolysis in white adipose tissue in a circadian clock-dependent manner (PMID 39094217).

Limits of the evidence in Module 1: none of the papers cited on this page is a human clinical trial of Stenabolic. There is no published dosage form, no standardised preparation, and no analytical survey in these papers of what research-grade material actually contains.

Module 2 — Mechanism as Described in the Literature

The receptor and the clock

REV-ERBα and REV-ERBβ repress transcription of clock genes including Bmal1, placing them inside the negative limb of the circadian oscillator. Pharmacological agonism was described as shifting circadian amplitude and period and altering clock gene expression across peripheral tissues in mice (PMID 22460951). Because the clock gates metabolic, immune and proliferative programmes, researchers have used REV-ERB as an entry point into all three.

Metabolic and lipid arms

A 2017 pharmacology review and research paper described REV-ERB's regulation of cholesterologenesis, linking receptor activity to the transcriptional control of cholesterol synthesis (PMID 28213272). The 2012 mouse work reported changes in metabolic gene expression together with increased energy expenditure, and in diet-induced obese animals reported reduced fat mass with improvements in dyslipidaemia and hyperglycaemia (PMID 22460951). Parallel genetic work shows the direction of clock manipulation matters: a 2021 study reported that deficiency of intestinal Bmal1 prevented obesity induced by high-fat feeding in mice (PMID 34493722), and a 2024 study reported that nobiletin, a different clock-directed molecule, promoted white adipose lipolysis only when the clock was intact (PMID 39094217).

Immune and inflammatory arm

A 2018 Nature Communications study reported that REV-ERBα integrates the colon clock with experimental colitis through regulation of the NF-κB/NLRP3 axis (PMID 30315268). In the central nervous system, a 2019 PNAS study reported that the circadian clock protein Rev-erbα regulates neuroinflammation, with loss of the receptor associated with heightened glial inflammatory activation (PMID 30792350), and a 2025 study reported that Nr1d1 regulated microglial M1/M2 polarisation and alleviated neuroinflammation after experimental traumatic brain injury (PMID 41296614). Clock disruption also runs the other way: a 2024 review-style analysis reported disrupted molecular clocks in monocytes and macrophages during allergic inflammation (PMID 38863703).

Proliferation and cell survival arm

A 2018 Nature paper reported that pharmacological activation of REV-ERBs was lethal to cancer cells and to oncogene-induced senescent cells, with the authors linking the effect to inhibition of autophagy and de novo lipogenesis (PMID 29320480). A 2023 Cancer Research study reported that NR1D1 stimulated antitumour immune responses in breast cancer models by activating cGAS-STING signalling (PMID 37395684).

Limits of the evidence in Module 2: much of the pathway map comes from genetic deletion rather than from the compound, so effects attributed to the receptor are not automatically effects of the molecule. None of the papers cited here established target selectivity for SR9009 in receptor-null tissue, measured off-target binding across a receptor panel, or demonstrated that the mechanism described in mouse tissue operates the same way in humans.

Module 3 — Reported Outcomes by Study

The table summarises the models, endpoints and directional findings as published. It is a record of what researchers observed in experimental systems, not a statement of benefit for any person.

Reading the outcome literature carefully

Two features recur. First, the metabolic findings are short-term rodent findings measured in gene expression, body composition and plasma chemistry, reported in a single influential 2012 paper (PMID 22460951) rather than replicated across independent human cohorts. Second, several outcomes are context-specific: the same receptor pathway was reported to reduce inflammation in colon and brain models (PMID 30315268, PMID 41296614) while activation was reported as cytotoxic in cancer and senescent cells (PMID 29320480). Adjacent clock pharmacology reinforces the context dependence — a 2024 study reported that the vitamin D analogue ED-71 improved osteogenesis in diabetic bone loss by upregulating BMAL1 (PMID 39224902), whereas a 2023 study reported that 7,8-dihydroxyflavone alleviated cardiac fibrosis by downregulating a Bmal1/Akt pathway (PMID 36427535).

Limits of the evidence in Module 3: no cited study measured athletic performance, endurance, strength, body composition or cardiometabolic risk in humans. Rodent endpoints were short-term, animals were typically young and inbred, and no cited paper reported a long-term survival or hard-outcome analysis for the compound.

Module 4 — Stenabolic Side Effects: What Studies Report

Because the verified literature is preclinical, "adverse events" here means what researchers observed in animals and cells, not what was catalogued in a monitored human trial. No human safety dataset appears in these papers.

• Cytotoxicity as an on-target effect. The 2018 Nature study reported that pharmacological REV-ERB activation was lethal to cancer cells and to oncogene-induced senescent cells, with autophagy inhibition described as part of the mechanism (PMID 29320480). Autophagy blockade is a cell-survival liability, and the study characterised normal tissue as comparatively spared at the exposures used rather than demonstrating an absence of risk (PMID 29320480).
• Circadian behavioural change. The 2012 mouse work reported altered circadian behaviour in constant darkness along with shifted clock gene rhythms in multiple peripheral tissues (PMID 22460951). Altered rhythmicity was the intended pharmacological signal in that study; it is also, by definition, a disturbance of a physiological rhythm.
• Pathway-level inflammatory risk. Studies that manipulated the receptor genetically reported that loss of Rev-erbα increased inflammatory activation in the brain (PMID 30792350) and that REV-ERBα sits upstream of NF-κB/NLRP3 signalling in colon (PMID 30315268), which indicates that pushing this node in either direction has immune consequences.
• Immune-surveillance considerations. A 2023 study reported that NR1D1 modulated antitumour immune signalling through cGAS-STING (PMID 37395684), and a 2024 analysis reported clock disruption in monocytes and macrophages during allergic inflammation (PMID 38863703), so immune timing is a plausible domain for unintended effects.

Limits of the evidence in Module 4: there is no published human adverse-event profile, no dose-limiting toxicity study in people, no reproductive or developmental toxicology, and no cardiac, hepatic or renal safety monitoring data for Stenabolic in the cited papers. Absence of reported harm in short rodent experiments is not evidence of safety.

Module 5 — Pharmacokinetics Where Data Exist

This is the thinnest module, and the honesty of the gap matters more than any inference. Among the papers cited here, none reported human pharmacokinetic parameters for SR9009 — no oral bioavailability figure, no plasma half-life, no volume of distribution, no clearance route, no tissue-distribution table for people. The 2012 Nature report described in vivo administration to mice and measured downstream tissue gene expression and whole-animal metabolic endpoints rather than presenting human exposure data (PMID 22460951), and the 2018 cancer study used systemic administration in mouse tumour models as a pharmacological tool (PMID 29320480).

Two practical implications follow from that gap. First, because no cited study established oral exposure in humans, claims circulating about oral activity cannot be traced to the papers summarised here. Second, because REV-ERB effects are rhythm-dependent, timing of exposure would be a pharmacological variable rather than a detail — a point illustrated by clock-dependent findings such as a 2024 report that lipolysis induced by nobiletin required an intact clock (PMID 39094217).

Limits of the evidence in Module 5: no absorption, distribution, metabolism, excretion or drug-interaction data for humans appear in the cited literature, and no metabolite identification or active-metabolite characterisation is available from these papers.

Module 6 — Regulatory Status, Stated Factually

The following is regulatory context, not legal advice; rules differ by country and change over time.

1. No approved product. SR9009 is not an active ingredient in any medicine approved by the US Food and Drug Administration, the European Medicines Agency or comparable regulators. There is no approved indication, label, or prescribing information.
2. Research-use-only status. Material is distributed for laboratory research and is labelled research use only, meaning it is not intended for human or veterinary use, has not been evaluated for human administration, and is not manufactured to pharmaceutical quality standards.
3. Dietary supplements. A synthetic drug-like molecule of this kind does not meet the statutory definition of a dietary ingredient in the United States, and US regulators have repeatedly warned that body-building products marketed as containing investigational drug-class compounds are unapproved drugs when sold for human use.
4. Compounding. Pharmacy compounding in the United States generally depends on an active ingredient that is a component of an FDA-approved drug, is the subject of an applicable USP monograph, or appears on an FDA bulk drug substances list. SR9009 does not satisfy those routes, so it is not a lawfully compoundable substance.
5. Sport. SR9009 has been named on the World Anti-Doping Agency Prohibited List within the metabolic modulator category, meaning its presence is an anti-doping rule violation for tested athletes at all times.

Limits of the evidence in Module 6: regulatory status is a legal fact, not a safety verdict. Being unapproved does not mean a molecule is dangerous, and being research-grade says nothing about purity or identity of any particular sample; conversely, none of the cited studies was designed to support a marketing application.

What the Studies Did Not Test

Closing a course on this compound means naming the empty cells in the evidence table.

• Humans. No cited paper reported a clinical trial of Stenabolic in healthy volunteers or patients, so efficacy, tolerability and dose–response in people are untested in this literature.
• Exercise performance. Endurance, VO₂ metrics, strength and training adaptation were not endpoints in the cited studies; the metabolic findings were tissue gene expression, energy expenditure, fat mass and plasma chemistry in mice (PMID 22460951).
• Target specificity of the molecule. The cited studies did not verify that the compound's effects require REV-ERB, which is why the receptor biology papers (PMID 30792350, PMID 37395684) and the compound papers should be read as separate lines of evidence.
• Chronic exposure. Long-term dosing, cancer incidence, fertility, and effects on developing organisms were not examined in the cited work, despite evidence that the pathway touches senescence and autophagy (PMID 29320480).
• Interactions. No cited study tested combinations with medicines, other research compounds, or shift-work and sleep-restriction conditions, even though clock disruption itself was reported in immune cells during allergic inflammation (PMID 38863703).
• Bone, heart and gut translation. Adjacent clock-pharmacology findings in bone (PMID 39224902), heart (PMID 36427535) and intestine (PMID 34493722) involved different molecules or genetic models and cannot be read as Stenabolic outcomes.

Read as a whole, the literature describes an interesting receptor and a chemical probe that helped reveal it. That is a different claim from a characterised therapeutic, and the distinction is the single most useful thing this course can leave behind.

References

• Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists (Nature, 2012)
• Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence (Nature, 2018)
• REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis (Nature Communications, 2018)
• Circadian clock protein Rev-erbα regulates neuroinflammation (PNAS, 2019)
• Nr1d1 Regulates Microglia M1/M2 Polarization to Alleviate Neuroinflammation after Traumatic Brain Injury (ACS Chemical Neuroscience, 2025)
• Rev-erb regulation of cholesterologenesis (Biochemical Pharmacology, 2017)
• NR1D1 Stimulates Antitumor Immune Responses in Breast Cancer by Activating cGAS-STING Signaling (Cancer Research, 2023)
• The disrupted molecular circadian clock of monocytes and macrophages in allergic inflammation (Frontiers in Immunology, 2024)
• Nobiletin promotes lipolysis of white adipose tissue in a circadian clock-dependent manner (The Journal of Nutritional Biochemistry, 2024)
• Deficiency of intestinal Bmal1 prevents obesity induced by high-fat feeding (Nature Communications, 2021)
• ED-71 Ameliorates Bone Loss in Type 2 Diabetes Mellitus by Enhancing Osteogenesis Through Upregulation of the Circadian Rhythm Coregulator BMAL1 (Drug Design, Development and Therapy, 2024)
• 7,8-Dihydroxyflavone alleviates cardiac fibrosis by restoring circadian signals via downregulating Bmal1/Akt pathway (European Journal of Pharmacology, 2023)